Čović

La Jolla Institute for Immunology Acquires the Carterra LSA Platform to Advance State-of-the-Art Immunological and Infectious Disease Research

Retrieved on: 
Monday, August 1, 2022
Health, Medical Devices, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, La Jolla Institute for Immunology, Antibody, Mab, Bamlanivimab, Čović, NIH, Time, Pandemic, Industry, NIAID, Research, Software, Cros, Institute, Health, Immune system, COVID-19, Multimedia, Bill & Melinda Gates Foundation, LSA, Eli Lilly, Technology, Disease, FDA, Method, Life, Microfluidics, Therapy, Autoimmunity, Sera, PerkinElmer, AbCellera, Vaccine, Pharmaceutical industry, Immunology, Science

It was through this collaboration that LJI discovered the power and magnitude of the LSAs capabilities.

Key Points: 
  • It was through this collaboration that LJI discovered the power and magnitude of the LSAs capabilities.
  • The LSA will also enable the rapid characterization of sera samples from vaccine studies, in addition to autoimmune and cancer targets.
  • Were proud to see the benefit of Carterras LSA platform being brought to bear for global good, says Tim Germann, Chief Commercial Officer at Carterra.
  • Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease.

University of Manchester Adds Carterra’s LSA® Instrument for High-Throughput Antibody Screening and Characterization

Retrieved on: 
Wednesday, June 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, University, Education, Manchester, University of Manchester, Eli Lilly, Cros, Time, Mab, Research, PerkinElmer, Immunoassay, Čović, Social responsibility, Software, AbCellera, Partnership, Wellcome Trust, NHS, University, Method, Faculty, LSA, Technology, COVID-19, Antibody, Bamlanivimab, Industry, Tissue, Microfluidics, Surface plasmon resonance, Education, VHH, Pharmaceutical industry, Fine chemical, Biochemistry, Biology, Medicine, Health

The BACF also supports research at other higher education institutions in the UK as well as in the pharmaceutical industry.

Key Points: 
  • The BACF also supports research at other higher education institutions in the UK as well as in the pharmaceutical industry.
  • The LSA will allow university researchers to cast a wider net and screen more nanobodies per target, thereby increasing the likelihood of identifying the ideal hit.
  • We cant wait to use the LSA for our development and characterization of nanobodies for which Carterras instrument is perfectly suited, commented Dr. Tom Jowitt, the Manager of the BACF.
  • Carterras LSA instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems.

Genovac Acquires the Carterra LSA® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services

Retrieved on: 
Wednesday, April 20, 2022
Biotechnology, Pharmaceutical, Health, Medical Devices, Technology, Beacon, COVID-19, Software, Research, Čović, LSA, Bamlanivimab, Science, NIAID, PerkinElmer, Method, Microfluidics, Immortalised cell line, Mab, Multimedia, Antibody, Disease, Eli Lilly, Industry, Cros, Time, Kropyvnytskyi Region Universal Research Library, AbCellera, Berkeley, Fine chemical, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220420005500/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220420005500/en/
    Genovac Acquires the Carterra LSA Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services (Photo: Business Wire)
    Genovac, previously a part of Aldevron before a management buyout in 2020, has been providing discovery services to life science researchers since 1999 from its site in Freiburg, Germany.
  • Were thrilled to add Carterras LSA, the most advanced, high-throughput epitope binning and affinity measuring platform in the world, to our Fargo facility.
  • Like Carterra, Genovac is completely committed to serving their clients with the most advanced technologies and services in biologics discovery.
  • Its immunization technologies, combined with multiple single-cell screening technologies, including Berkeley Lights Beacon, enable success against the most challenging targets.

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

Retrieved on: 
Thursday, September 23, 2021
Technology, Research, Infectious Diseases, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Science, Blood, NGS, Animal, Weight loss, La Jolla Institute for Immunology, Risk, RNA, Security (finance), Therapy, Top of the Form (quiz show), USAMRIID, Private Securities Litigation Reform Act, DNA, Doctor of Philosophy, Immunoglobulin G, U.S. Securities and Exchange Commission, Patient, Engineering, Infection, Martek Biosciences Corporation, COVID-19, Twist Bioscience, Biology, CEO, N501Y, Human, Genomics, Antibody, Agriculture, Immunology, Technology, Severe acute respiratory syndrome coronavirus 2, VHH, Synthetic biology, RBD, Silicon, Drug discovery, ACE2, United States Army Medical Research Institute of Infectious Diseases, Peplomer, Čović, Time, Urinary tract infection, Mutation, SEC, Vaccine, Pharmaceutical industry, Twist Biopharma Antibodies, The Coronavirus Immunotherapy Consortium (CoVIC), Twist Bioscience Corporation, TWIST BIOPHARMA ANTIBODIES, THE CORONAVIRUS IMMUNOTHERAPY CONSORTIUM (COVIC), TWIST BIOSCIENCE CORPORATION

TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.

Key Points: 
  • TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.
  • This makes it an important and viable candidate for clinical testing in combination with other antibody therapeutics.
  • TB202-3 binds to a majority of known mutations, with the exception of the L452R mutation present in the Delta and Epsilon variants.
  • Target recognition by VHH single domains, on the other hand, requires just a single domain found on heavy chain only antibody.